Clinical Trials – Page 26

ADC Therapeutics Showcases Promising Zynlonta Data in Marginal Zone Lymphoma and Secures $105M in Funding

12 months ago talkbio0Tagged Antibody-Drug Conjugates, Biotechnology, Cancer Therapeutic Procedure, Clinical Trials, Health care facility, Mucosa-Associated Lymphoid Tissue Lymphoma, Sales - occupational activity, therapeutic autologous dendritic cells, Zynlonta

ADC Therapeutics, Zynlonta, marginal zone lymphoma, share sale, funding, cancer treatment, antibody-drug conjugate, clinical trials, biotechnology, healthcare.

Chiesi Invests Heavily in Gossamer’s Promising Pulmonary Hypertension Treatment

12 months ago talkbio0Tagged Cardiovascular Diseases, Chiesi, Clinical Trials, Collaboration, Drug Development, GD-001, Gossamer, Investments, Pulmonary Hypertension

Chiesi, Gossamer, pulmonary hypertension, drug development, investment, collaboration, GD-001, clinical trials, cardiovascular diseases.

GlycoMimetics’ Uproleselan Fails to Meet Primary Endpoint in Leukemia Clinical Trial

12 months ago talkbio0Tagged Clinical Trials, GlycoMimetics, leukemia, Primary Endpoint, Stock Market Reaction, Uproleselan

GlycoMimetics, Uproleselan, Leukemia, Clinical Trial, Primary Endpoint, Stock Market Reaction

CG Oncology’s Immunotherapy Shows Promising Complete Response Rate in Bladder Cancer Patients

12 months ago talkbio0Tagged Cancer Therapeutic Procedure, centigram, Clinical Trials, Immunotherapy, Malignant neoplasm of urinary bladder, Neoplasms

CG Oncology, immunotherapy, bladder cancer, complete response rate, clinical trials, cancer treatment.

Amgen Discontinues Obesity Program, Shifts Focus to MariTide after Phase 1 Results

12 months ago talkbio0Tagged amgen, asset, Biotechnology, Clinical Trials, Drug Development, MariTide, Obesity, Phase 1 (qualifier value)

Amgen, obesity asset, phase 1 results, MariTide, drug development, biotechnology, clinical trials

Controversy Surrounds FDA’s Fast-Track Approval of Sarepta’s Duchenne Muscular Dystrophy Gene Therapy

12 months ago talkbio0Tagged Accelerated, Advocacy, Approved, Clinical Trials, DMD, Duchenne, Effectiveness, gene therapy, Muscular Dystrophy, Muscular Dystrophy, Duchenne, Regulation of biological process, Safety, United States Food and Drug Administration

FDA, Sarepta Therapeutics, Duchenne Muscular Dystrophy (DMD), gene therapy, accelerated approval, controversy, clinical trials, efficacy, safety, patient advocacy, regulatory process.

Reunion Neuroscience Secures $103 Million to Advance Psychedelic Therapies for Patients

12 months ago talkbio0Tagged Clinical Trials, Industry, mental health, mental health innovation, Neuroscience discipline, patient care, psychedelic therapies, Reunion Island

Reunion Neuroscience, psychedelic therapies, mental health, fundraising, clinical trials, mental health treatments, alternative therapies, mental health innovation, patient care, biotech industry.